Clinical Trials Directory

Trials / Completed

CompletedNCT00172003

Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Novartis Pharmaceuticals · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

It is the aim of this clinical study to evaluate the skeletal-related event rate under therapy with zoledronic acid in patients with renal cell cancer having at least one cancer-related bone lesion.

Conditions

Interventions

TypeNameDescription
DRUGZoledronic acid

Timeline

Start date
2004-09-01
Primary completion
2009-07-01
Completion
2009-07-01
First posted
2005-09-15
Last updated
2016-11-18

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT00172003. Inclusion in this directory is not an endorsement.

Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis (NCT00172003) · Clinical Trials Directory